Anzeige

Archive

Clopidogrel pretreatment in primary percutaneous coronary intervention: Prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
DOI: https://doi.org/10.1160/TH13-01-0057
Issue: 2013: 110/1 (July) pp. 1-204
Pages: 110-117

Clopidogrel pretreatment in primary percutaneous coronary intervention: Prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery

J. L. Ferreiro (1), S. Homs (1), J. Berdejo (1), G. Roura (1), J. Gómez-Lara (1), R. Romaguera (1), L. Teruel (1), G. Sánchez-Elvira (1), A. L. Marcano (1), J. A. Gómez-Hospital (1), D. J. Angiolillo (2), Á. Cequier (1)

(1) Heart Diseases Institute, Bellvitge University Hospital – IDIBELL, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain; (2) University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, USA

Keywords

Antiplatelet therapy, ST-elevation myocardial infarction, Clopidogrel responsiveness

Summary

To date, there is limited data on levels of platelet inhibition achieved in patients with ST-elevation myocardial infarction (STEMI) who are loaded with clopidogrel and aspirin (ASA) prior to undergoing primary percutaneous coronary intervention (P-PCI). The aim of this investigation was to evaluate the percentage of STEMI patients with high on-treatment platelet reactivity (HPR) to clopidogrel at the time of initiating P-PCI and its association with the initial patency of the infarct-related artery (IRA). This prospective pharmacodynamic study included 50 STEMI patients, previously naïve to oral antiplatelet agents, who received 500-mg ASA and 600-mg clopidogrel loading doses prior to P-PCI. Platelet function assessment was performed at the beginning of the procedure using various assays, including VerifyNow™ system (primary endpoint), light transmission aggregometry and multiple electrode aggregometry. The percentage of patients with suboptimal response to clopidogrel and ASA assessed with the VerifyNow™ system was 88.0% and 28.6%, respectively. Similar results were obtained with the other assays used. A higher percentage of patients with initial patency of the IRA was observed among those patients without HPR compared with those with HPR to clopidogrel (66.7% vs 15.9%; p=0.013), while no differences were observed regarding postprocedural angiographic or electrocardiographic outcomes. In conclusion, this study shows that a high percentage of STEMI patients have inadequate levels of clopidogrel-induced and, to a lesser extent, aspirin-mediated platelet inhibition when starting a P-PCI procedure, and suggests that a poor response to clopidogrel might be associated with impaired initial TIMI flow in the IRA.

You may also be interested in...

1.

Online Supplementary Material

O. De Backer (1), H. Ratcovich (1), L. Biasco (1), F. Pedersen (1), S. Helqvist (1), K. Saunamäki (1), H.-H. Tilsted (1), P. Clemmensen (1), G. Olivecrona (1), H. Kelbaek (1), E. Jørgensen (1), T. Engstrøm (1), L. Holmvang (1)

Thromb Haemost 2015 114 3: 623-631

https://doi.org/10.1160/TH15-01-0026

2.
Francesca Cesari 1, Rossella Marcucci 1, Roberto Caporale 2, Rita Paniccia 1, Eloisa Romano 1, Gian Franco Gensini 3, Rosanna Abbate 1, Anna Maria Gori1

Thromb Haemost 2008 99 5: 930-935

https://doi.org/10.1160/TH08-01-0002

3.

T. Bömicke (1), C. M. Valina (1), C. Stratz (1), M. Amann (1), F.-J. Neumann (1), W. Hochholzer (1)

Thromb Haemost 2017 117 8: 1644-1650

https://doi.org/10.1160/TH17-02-0122